Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FDY-8801
- Development stage
- Preclinical
- Lead developer
- Faraday Pharmaceuticals
- Modality
- Small Molecules
01
Overview
FDY-8801 is an investigational drug candidate being developed by Faraday Pharmaceuticals for the treatment of cachexia and muscle wasting. Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the prevention and treatment of cardiac and skeletal muscle loss. FDY-8801 is part of the company's cachexia portfolio, which also includes the more advanced candidate FDY-7001 (S-oxprenolol). As of early 2024, FDY-8801 is in the early stages of development (discovery or preclinical), and specific details regarding its biological target, mechanism of action, and chemical modality have not been publicly disclosed by the company.
Beyond the preview
Go deeper on FDY-8801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FDY-8801.